	US 12,144,824 B2
	Method for enhancing embryo implantation
Kelton Paul Tremellen, Bedford Park (AU); David K Gardner, Parkville (AU); and Alexandra J. Harvey, Parkville (AU)
Assigned to NULIFE B.V., Rotterdam (NL)
Appl. No. 17/059,221
Filed by The Flinders University of South Australia, Bedford Park (AU); and The University of Melbourne, Parkville (AU)
PCT Filed May 29, 2019, PCT No. PCT/AU2019/000067 § 371(c)(1), (2) Date Nov. 26, 2020, PCT Pub. No. WO2019/227122, PCT Pub. Date Dec. 5, 2019.
Claims priority of application No. 2018901900 (AU), filed on May 29, 2018.
Prior Publication US 2021/0213053 A1, Jul. 15, 2021
Int. Cl. A61K 33/34 (2006.01); A61B 17/43 (2006.01); A61B 17/435 (2006.01); A61K 9/06 (2006.01); A61K 9/08 (2006.01); A61K 9/14 (2006.01); A61K 33/30 (2006.01); A61K 47/10 (2017.01); A61K 47/38 (2006.01)

CPC A61K 33/34 (2013.01) [A61B 17/43 (2013.01); A61B 17/435 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 9/14 (2013.01); A61K 33/30 (2013.01); A61K 47/10 (2013.01); A61K 47/38 (2013.01)]

14 Claims

1. A method of enhancing embryo implantation in a subject, wherein the method comprises administering to a uterine cavity of the subject a formulation comprising copper, wherein the copper is provided in solution or gel form,

(i) wherein the subject is hoping to achieve pregnancy through natural conception, and the formulation is administered to the subject in the same menstrual cycle prior to ovulation, or

(ii) wherein the subject is undergoing treatment by assisted reproductive technology involving the transfer of embryo, and the formulation is administered to the subject in the same menstrual cycle prior to embryo transfer, or

(iii) wherein the subject is undergoing treatment by intra-uterine insemination (IUI), and the formulation is administered to the subject in the same menstrual cycle prior to IUI,

wherein the formulation is administered to the uterine cavity of the subject in an amount effective to stimulate endometrial production of leukaemia inhibitory factor (LIF) and vascular endothelial growth factor (VEGF),

wherein the copper is provided to the uterine fluid cavity for a period no longer than 60 minutes.